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reimbursable drugs, has abolished the requirement, highlighting the potential prac-
tical difficulties in obtaining such prices. One country (Switzerland) has recently 
proposed amendments to its IRP methodology to focus on discounted rather than 
listed prices. ConClusions: IRP is increasing as a core market access risk globally, 
with the knock-on implications of low prices or price cuts in one country into other 
countries becoming a more tangible and complex threat. IRP is increasing both 
in terms of geographic scope and also in terms of the precise method of use. The 
shift from using manufacturing prices towards discounted prices, and the increas-
ing transparency over net prices, represent a significant ongoing threat, and the 
practical implications are wide-ranging. It has the counter-productive effective of 
rendering pharmaceutical companies less willing and likely to engage in discounts.
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objeCtives: Implemented by the Italian Medicines Agency (AIFA) in 2013, Class 
C-nn (C – non negotiated) was created to make all drugs approved by the European 
Medicines Agency (EMA) available to patients at prices set by manufacturer before 
AIFA’s pricing & reimbursement (P&R) decision. The study’s objective is to challenge 
the intended purpose of Class C-nn and its impact on the time to market. Methods: 
Drugs assigned to Class C-nn between January 2013 and April 2015 were consid-
ered for the analysis. Nine official dates, representing key milestones in the national 
market access process, from EMA approval to the P&R decision were identified; the 
period from AIFA’s Technical-Scientific Committee’s (CTS) opinion to the P&R deci-
sion was the main focus. The negotiation lengths were compared to those prior to 
the introduction of Class C-nn. Moreover, the relationship between drug-specific vari-
ables (e.g., therapeutic area, presence of registry, orphan/innovative status) and the 
negotiation length was analyzed. Results: Out of 137 products assigned to Class 
C-nn, 43 completed the P&R process. The average time from EMA approval and CTS’s 
opinion to the P&R decision totaled 393 days (95% CI 353-432) and 159 days (95% 
CI 137-181) respectively. The analysis revealed longer negotiations for oncology and 
diabetes drugs versus drugs targeting other therapeutic areas. Negotiations for drugs 
included in the AIFA monitoring system were almost twice as long as products not 
monitored. It is worth noting that orphan drugs as well as drugs with an innovative 
status did not result in shorter negotiation processes. Furthermore, a negligible num-
ber of drugs accessed the market with C-nn status at freely set prices. ConClusions: 
Implementing Class C-nn has not significantly impacted the time to reimbursement 
in Italy. Most companies prefer to not submit freely set prices prior to the P&R deci-
sion, thus neglecting the possibility of early market access.
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objeCtives: Erythropoiesis-stimulating agents (ESAs) are not anymore part of 
listed drugs exceptionally financed in addition to DRGs tariffs, which use and 
expenditures are monitored by the authorities. The amount of ESAs has been 
included in French DRGs tariffs since March 2014. The objective is to assess 
the impact on both the activity and the budget of Public Hospitals of Paris (AP-
HP). Methods: A before-after study (March-September in 2013 versus in 2014) 
was conducted in acute care hospitals of AP-HP. Data from PMSI hospital database 
(French medical information system program) and finance and logistics software 
(SAP), were used to estimate the number and costs of DRGs with ESAs use in 2014, 
from 2013 data. Two hypotheses were performed: A) the activity was constant, 
B) it depended on ESAs volumes delivered by hospital pharmacies to care units 
(Wilcoxon test). Then a budget impact (BI) analysis was conducted, considering: i) 
costs of dialysis and extra dialysis DRGs with ESAs use in 2013 versus in 2014, ii) 
the loss of money earned in 2013 by negotiating ESAs prices below the reimbursed 
tariffs, iii) costs of ESAs included in the DRGs tariffs in 2014. Results: 20 hospitals 
were included. The number of DRGs with ESAs increased of 264 (+5%) dialysis DRGs 
and 80 (+2%) other DRGs under hypothesis A whereas it decreased of 449 (-9%) 
dialysis DRGs and it increased of 346 (+9%) other DRGs under hypothesis B, but this 
differences are not significant. Nevertheless, the global BI is between -€ 1,018,476 
(hypothesis A) and -€ 695,693 (hypothesis B) in 7 months. ConClusions: This 
study shows no significant impact on the hospital activity but a negative BI for 
AP-HP. This infers that the DRG-based payment may be not appropriate to the 
chronic renal failure. Besides, the French Health Ministry is working on a patient 
pathway-based payment.
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objeCtives: Aim: To investigate compliance with the recently introduced (November 
2013) system of active substance-based generic substitution and reference pricing (GS/
RP) in Ireland. Under GS/RP, a fixed drug price is paid by the Health Service Executive 
(HSE). Where a patient requests a premium-priced product, the patient must pay the 
difference. A prescriber may alternatively request ‘Do not substitute’(DNS), in which 
case the HSE pays the difference, similar to the Danish model where the prescriber 
may apply for reimbursement on behalf of patients. This study characterised Irish 
DNS trends and costs following GS/RP introduction. Methods: Pharmacy claims 
data from the ‘General Medical Services’ scheme, January 2013-October 2014 inclu-
sive, were analysed using SAS®v9.3. Drugs for which premium-priced products were 
available were studied where 6 months of follow-up data existed post policy introduc-
was approved in February 2015 but has not been assessed yet. Of note, MA for MACI® 
and Provenge®were suspended for commercial reasons. ConClusions: Market 
access of ATMPs is challenging as the evidence available at market launch might 
not be sufficient to address the HTA agencies’ expectations. Adaptive pathways for 
licencing and coverage of drugs might be a relevant approach for these medicines 
to reduce uncertainty through real-world data collection post-launch.
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objeCtives: In recent years pharmaceutical market in Poland was impacted by 
the new Reimbursement Act that came into the force on 1st January 2012. After 
a long period of stagnancy in pricing & reimbursement policy the new Act intro-
duced substantial changes. It was strongly awaited by all stakeholders. The aim of 
this study was to investigate the impact of the new Reimbursement Act on phar-
maceutical industry and market access. Methods: Medline, grey literature and 
other internet resources (health authorities’ websites, pharmaceutical blogs and 
discussion forums) search focused on implications of the new drug regulation in 
Poland. Results: The main objectives of the Reimbursement Act included improve-
ment of pricing and reimbursement process transparency, increase in overall access 
to medicines and to innovative drugs in particular, lowering patients’ co-payment 
and reduction of National Health Fund (NFZ) spending on reimbursable drugs. 
However, in pharmaceutical industry opinion the reform did not increase trans-
parency of reimbursement decision-making in Poland. While NFZ is considered to 
be the main beneficiary, industry revenue decreased. The new Act forced substantial 
adjustments in business models and incurred additional costs resulting from the 
need for intense monitoring of dynamically changing market situation. Access to 
innovative therapies is gradually improving with 29 innovative molecules intro-
duced to reimbursement lists between January 2012 and June 2014. NFZ expenditure 
on innovative drugs increased from 0,2% to 3% of total drug expenditure between 
2012 and 2014. In spite of some improvements, access to innovative therapies 
in Poland remains lower than in developed EU countries. ConClusions: New 
law influenced drug market substantially. It evoked many controversies and 
discussions. Overall, introduced changes are perceived as unfavorable by pharma-
ceutical industry. However, savings have been reallocated to fund new innovative 
therapies. Access to such therapies is slowly improving, but is still limited as com-
pared to Western EU countries.
PHP28
tHe evolvIng lanDscaPe oF early access PrograMMes: coMParIsons 
anD IMPlIcatIons For Market access
Heathfield A1, Lebiecki J1, Young KE2, Urbinati D3, Soussi I4, Toumi M5
1Pfizer, Surrey, UK, 2Creativ-Ceutical, Milan, Italy, 3Creativ-Ceutical, Luxembourg, Luxembourg, 
4Creativ-Ceutical, Tunis, Tunisia, 5Aix-Marseille University, Marseille, France
objeCtives: This study intends to provide an overview of regulatory updates on 
Early Access Programmes (EAPs) in 21 countries and score the drivers of successful 
implementation by examining the national regulatory framework, process, require-
ments, and revenue opportunity. Methods: A literature review was conducted 
from government and health authority websites, Pubmed, and grey literature to 
identify EAP regulation, practice, and updates. We inputted information in an Excel 
template and aggregated it with 3 indicators (clarity of the process, ease of imple-
mentation, and revenue possibility). The 3 indicators were ranked from 1 (least feasi-
ble, multiple barriers) to 4 (most feasible, least barriers). Geographical scope covered: 
France, Germany, Italy, Spain, UK, Austria, Belgium, Denmark, Norway, Poland, 
Portugal, Sweden, Switzerland, Australia, Brazil, Canada, Israel, New Zealand, South 
Africa, South Korea, and Turkey. Results: Regulatory updates were found in the 
countries with variable magnitude. Scores as follows: ++++: France; +++: Spain, 
Italy, Austria, Denmark, Norway, Canada, Israel, Australia, and New Zealand; ++: 
Germany, Portugal, Sweden-CUP, Switzerland, Brazil, South Africa, South Korea, 
Turkey; and +: UK, Belgium, and Poland. France, a pioneer in EAPs, scored highest. 
+++ countries have clear processes, free pricing, and possible reimbursement. In ++ 
countries, EAP sales are not possible. For UK and Belgium, processes are relatively 
new (2014) with steep fees, and are yet to be validated. Sales are not possible in 
the UK and details for Belgium are still unavailable. ConClusions: EAP policies 
are evolving fast, signaling high interest, and will likely be increasingly important. 
Regulatory changes tend to ease and expedite the EAP process but fees are being 
imposed and sales limited in newer regulations. It is yet to be seen how updates will 
affect the market access condition of products undergoing EAP. Companies must be 
abreast with changes to capitalise on early access opportunities and mitigate risks.
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objeCtives: The goal of this research is to understand the extent to which payers 
around the world are using discounted or net prices for international reference 
pricing (IRP) purposes as an alternative to list, manufacturing or wholesale prices. 
The research also examines what sources are being used to obtain these discounted 
prices. Methods: Primary research was conducted with payers in 45 countries to 
establish the methodology of IRP in those countries. Specific questions were asked 
around both the current and potential future use of different types of prices for IRP. 
This was supplemented with secondary search and literature reviews of legislation 
and healthcare sources related to IRP to understand mechanisms of IRP. Results: 
Overall, it was shown that 8 countries used some form of discounted prices for IRP 
purposes, and that the number of countries is increasing. In addition, one country 
(Bulgaria), which previously had a requirement to reference discounted prices for 
